Please login to the form below

Not currently logged in
Email:
Password:

Kosan out licenses motilin receptor agonist to Pfizer

Kosan Biosciences says that Pfizer has initiated a phase 1 clinical trial of its motilin receptor agonist PF-04548043 under development for the treatment of gastroesophageal reflux disease and other GI disorders

US biotech Kosan Biosciences has revealed that Pfizer initiated a phase 1 clinical trial of its motilin receptor agonist PF-04548043 under development for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) disorders.

The phase 1 clinical trial will test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects. Motilin is a hormone secreted by the small intestine and stimulates gastrointestinal movement. Motilin activity is mediated through the G-protein coupled motilin receptor found on smooth muscle cells of the GI tract and elements of the enteric nervous system.

In preclinical studies, PF-04548043 showed an improved safety profile relative to erythromycin and accelerated gastric emptying, suggesting that it may provide symptom relief in several GI diseases.

In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan's motilin agonist programme in a deal worth USD 250m for the successful development and commercialisation of PF-04548043 for one indication, as well as royalties on global sales.

Hsp990 inhibitor registration trials open
In other news, Kosan has opened the Tanespimycin in Myeloma Evaluation registration programme (TIME-2 trial) and has been enrolling patients for its lead Hsp90 inhibitor, tanespimycin (KOS-953).

The TIME programme includes two clinical trials: TIME-1 and TIME-2. TIME-1 is a pivotal phase III trial to be conducted in a first-relapse patient population. TIME-2, which is designed to be supportive of the TIME-1 trial, is a phase II/ III trial in patients with relapsed-refractory disease.

TIME-2 also has the potential to support registration in a relapsed-refractory setting. The TIME program will use Kosan's new, proprietary injectable suspension formulation of tanespimycin, which will be the first Hsp90 inhibitor to enter such a programme.

7th August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...